Prophylaxis and treatment of gastrointestinal complications following transplantation

Clinical Transplantation

Volumn 15, Issue SUPPL. 4, 2001, Pages 29-35

  Harold Helderman, J ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

GI complications; Prophylaxis; Transplantation; Treatment

Indexed keywords

ACICLOVIR; AMPHOTERICIN; ANTACID AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; BISMUTH DERIVATIVE; CIMETIDINE; COTRIMOXAZOLE; CYCLOSPORIN; GANCICLOVIR; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; METRONIDAZOLE; MISOPROSTOL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; NYSTATIN; PENICILLIN G; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR; RAPAMYCIN; STEROID; SUCRALFATE; TACROLIMUS; VANCOMYCIN;

ARTICLE; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM ULCER; ENDOSCOPY; GASTROINTESTINAL INFECTION; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; METABOLIC DISORDER; MICROORGANISM; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; SURGICAL INJURY; TOXICITY; TRANSPLANTATION;

ENDOSCOPY, GASTROINTESTINAL; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RISK FACTORS;

EID: 0034981409     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2001.00029.x     Document Type: Article

References (50)

1. Mycophenolate mofetil, a rationally designed immunosuppressive drug
2. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide: A long-term case-control follow-up study
3. Cyclosporine nephrotoxicity
4. Inhibition of in vitro vascular endothelial cell proliferation and in vivo vascularization by low-dose methotrexate
5. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation
6. A comparison of FK506 (FK506) and cyclosporine for immunosuppression in liver transplantation
7. Gastroenterologic complications of organ transplantation
8. Incidence, complications, treatment, and outcome of ulcers of the upper GI tract after renal transplantation during the cyclosporine era
9. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
10. Gastrointestinal complications and appendicitis after kidney transplantation
11. Lesions of the upper gastrointestinal tract in patients with chronic renal failure
12. Peptic ulcer disease in the transplant recipient
13. Treatment of peptic ulcer disease in the renal transplant patient
14. Gastrointestinal complications after renal transplantation
15. Prevention of duodenal ulcer recurrence
16. Omeprazole
17. The influence of immunosuppression on peptic ulceration following renal transplantation and the role of endoscopy
18. An appraisal of drug interactions with Sandimmun
19. Cyclosporine-cimetidine interaction
20. Interactions of FK506 (tacrolimus) with clinically important drugs
21. Peptid ulcer disease following transplantation: The role of cimetidine
22. Prophylaxis of acute gastroduodenal bleeding after renal transplantation
23. Infection in the organ transplant recipient
24. Infections in solid-organ transplant recipients
25. Herpes simplex esophagitis after renal transplantation
26. Cytomegalovirus infection: A quantitative prospective study of 320 consecutive renal transplants
27. Incidence and treatment of candida esophagitis in patients undergoing renal transplantation. Data from the Minnesota prospective randomized trial of cyclosporine versus antilymphocyte globulin-azathioprine
28. Pancreatitis after cardiac and cardiopulmonary transplantation
29. Management of severe pancreatitis in renal transplant recipients
30. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients
31. Prophylaxis against herpes infections in kidney transplant patients with special emphasis on CMV
32. Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: Is it effective?
33. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
34. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients
35. Prophylaxis of cytomegalovirus infection in liver transplantation: A randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Data-base
36. Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients
37. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
38. Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir
39. Successful management of symptomatic cytomegalovirus disease after heart transplantation
40. Pancreatitis in patients with end-stage renal disease
41. Acute pancreatitis following liver transplantation
42. Microsporidia infection in transplant patients
43. Opportunistic infections with Strongyloides stercoralis in renal transplantation
44. Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients
45. Mycophenolate mofetil, microemulsion cyclosporine, and prednisone as primary immunosuppression for pediatric liver transplant recipients
46. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection
47. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients
48. Giant gastric ulcers and risk factors for gastroduodenal mucosal disease in orthotopic lung transplant patients
49. Colonic perforations after renal transplantation